RTP4

Across TCGA pan-cancer cohorts, RTP4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RTP4 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RTP4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RTP4 expression acts as an unfavorable survival marker.

BLCA, HNSC, and LIHC are the cancer types where RTP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.115	0.627	<.001	34	view →
HNSC	OS	Median	III,IV	0.087	0.746	<.001	24	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
CESC	DFS	Median	All	0.250	0.740	.030	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RTP4–BLCA (DFS)

Open the BLCA breakdown →